Used in targeted cancer therapy, particularly for acute myeloid leukemia (AML). Binds selectively to the FLT3 receptor (CD135) on leukemic cells, blocking abnormal signaling that drives uncontrolled cell growth. Employed in research and development of monoclonal antibody treatments, often as a reference standard in preclinical studies. Supports evaluation of drug efficacy, binding affinity, and functional neutralization in FLT3-expressing cell lines and patient samples. Also utilized in flow cytometry and immunohistochemistry to detect FLT3 expression in hematological malignancies.